Earnings summaries and quarterly performance for Surrozen, Inc./DE.
Executive leadership at Surrozen, Inc./DE.
Board of directors at Surrozen, Inc./DE.
Research analysts who have asked questions during Surrozen, Inc./DE earnings calls.
Recent press releases and 8-K filings for SRZN.
Surrozen Provides Update on Ophthalmology Pipeline and 2026 IND Filing Plans
SRZN
New Projects/Investments
Guidance Update
- Surrozen is focused on Wnt biology for tissue regeneration, particularly in ophthalmology for retinopathies, with its lead program SZN-8141 targeting Wnt and VEGF, and SZN-8143 adding IL-6 inhibition.
- The company plans to file an Investigational New Drug (IND) application for SZN-8141 in 2026, with SZN-8143 following several months later.
- Preclinical studies for SZN-8141 have demonstrated superiority to Eylea alone and Wnt alone in some retinopathy models, suggesting a synergistic effect.
- Surrozen ended the quarter with $80 million in cash and secured a $175 million PIPE (Private Investment in Public Equity), with $75 million received upfront and $100 million contingent upon FDA IND acceptance, which is expected to fund both programs through proof-of-concept data.
Dec 2, 2025, 2:30 PM
Surrozen Updates on Wnt Biology Pipeline and 2026 IND Filing Plans
SRZN
New Projects/Investments
Guidance Update
- Surrozen, founded in 2016, is focused on Wnt biology for tissue regeneration, particularly in ophthalmology for retinopathies.
- The company's lead program, SZN-8141, is a bispecific targeting Wnt and VEGF, with an Investigational New Drug (IND) filing planned for 2026. A second trispecific molecule, SZN-8143, which adds IL-6 inhibition, is expected to follow months later.
- Surrozen out-licensed a Wnt-only molecule to Boehringer Ingelheim for $12.5 million upfront and up to $500-$600 million in milestones, while retaining full ownership of SZN-8141 and SZN-8143.
- The company ended the quarter with $80 million in cash and secured a $175 million PIPE earlier in the year, with $75 million upfront and $100 million upon FDA IND acceptance, which is expected to fund both programs through proof of concept.
- Surrozen's Wnt component shows greater in vitro potency and superior results in rodent models compared to the Merck/EyeBio Wnt agonist, which demonstrated VEGF-like efficacy in 26 diabetic macular edema patients with 10 letters of visual acuity gain and 150 microns of retinal drying.
Dec 2, 2025, 2:30 PM
Surrozen (SRZN) Provides Update on Wnt-VEGF Bispecific Program SZN-8141 and Financial Runway
SRZN
New Projects/Investments
Guidance Update
- Surrozen (SRZN) is developing SZN-8141, a bispecific antibody targeting Wnt and VEGF for retinopathies, with an Investigational New Drug (IND) application planned for 2026.
- The company's approach aims for additive benefit by combining Wnt activation with VEGF antagonism, and preclinical data in mouse models suggest SZN-8141 is superior to Eylea alone and Wnt activation alone, indicating a synergistic effect.
- Surrozen out-licensed an earlier Wnt-only molecule to Boehringer Ingelheim for $12.5 million upfront and up to $500 million-$600 million in milestones, while retaining full ownership of SZN-8141 and SZN-8143.
- Surrozen reported $80 million in cash at the end of the quarter and expects an additional $100 million upon FDA acceptance of their IND, which is anticipated to fund both SZN-8141 and SZN-8143 through proof-of-concept data.
Dec 2, 2025, 2:30 PM
Surrozen Provides Update on Wnt Biology Pipeline and Financials
SRZN
Guidance Update
New Projects/Investments
- Surrozen is developing multi-functional antibodies for ophthalmology, combining Wnt agonism with VEGF and/or IL-6 inhibition to address retinopathies.
- The company plans to file an Investigational New Drug (IND) application for its lead candidate, 8141, in the U.S. in 2026.
- Surrozen secured a $175 million PIPE financing earlier this year, with the first tranche of $75 million covering operations past IND clearance and an additional $100 million available to fund through Phase 1B2A data readouts for 8141 and 8143.
- The company holds broad patents in the US, Europe, and Japan for multivalent antibodies targeting Frizzled LRP5 or 6, which may cover competitor molecules from Merck and Roche.
- Key competitor Merck's RESTRA studies (Brunello and Barolo) are anticipated to read out, with the first results expected in Q3 2026.
Nov 12, 2025, 2:30 PM
Surrozen Reports Q3 2025 Financial Results and Announces CFO Appointment
SRZN
Earnings
Management Change
New Projects/Investments
- Surrozen reported a net loss of $71.6 million, or ($8.36) per share, for the third quarter ended September 30, 2025, compared to a net loss of $1.4 million, or ($0.44) per share, for the same period in 2024. The company's cash and cash equivalents were $81.3 million as of September 30, 2025.
- Total revenue for Q3 2025 was $0.983 million, primarily from research service revenue, a decrease from $10.0 million in Q3 2024, which included collaboration and license revenue.
- Andrew Maleki was appointed Chief Financial Officer, effective November 12, 2025, bringing over a decade of experience in the biotech industry. Charles Williams will continue solely as Chief Operating Officer.
- The company continues to progress its ophthalmology pipeline and remains on track to submit an Investigational New Drug (IND) application for SZN-8141 in 2026.
Nov 7, 2025, 9:11 PM
Surrozen Discusses Ophthalmology Pipeline and Funding
SRZN
New Projects/Investments
Guidance Update
- Surrozen has pivoted its focus to retinal vascular disorders, with two lead programs: SZN-8141 (combining Frizzled-4 and VEGF) and SZN-8143 (combining Frizzled-4, VEGF, and IL-6).
- The company expects to file an Investigational New Drug (IND) application for SZN-8141 next year.
- Surrozen completed a $175 million financing earlier this year, with $76 million upfront to fund operations through the IND filing, and an additional $98 million second tranche to fund Phase 1/2a trials for both SZN-8141 and SZN-8143.
- The company holds broad intellectual property for its proprietary SWAP technology platform, which enables multivalent engagement receptors for Wnt activation.
Sep 4, 2025, 12:00 PM
Surrozen Provides Update on Ophthalmology Pipeline and Financing
SRZN
New Projects/Investments
Guidance Update
- Surrozen has pivoted its focus to ophthalmology, developing two lead programs for retinal vascular disorders: SZN-8141 (combines Frizzled-4 and VEGF) and SZN-8143 (combines Frizzled-4, VEGF, and IL-6).
- The company secured $175 million in financing this year, with $76 million upfront to fund through the IND filing for SZN-8141 and an additional $98 million to fund both SZN-8141 and SZN-8143 through Phase I/IIa trials.
- SZN-8141 is currently in CMC development, with an IND filing projected for next year.
- Surrozen recently obtained broad IP for its SWAP technology platform, covering multivalent engagement receptors for Wnt activation, which was cited as prior art against a Merck application.
Sep 4, 2025, 12:00 PM
Surrozen, Inc. enters into sales agreement for common stock offering
SRZN
- Surrozen, Inc. entered into a Sales Agreement with TD Securities (USA) LLC on August 29, 2025, to offer and sell shares of its common stock.
- The company may sell common stock with an aggregate offering price of up to $50.0 million.
- TD Securities (USA) LLC will act as the sales agent and will receive a commission of up to 3.0% of the gross sales proceeds.
- Sales of the shares can be made through various methods, including "at the market offering" on the Nasdaq Capital Market.
Aug 29, 2025, 8:58 PM
Quarterly earnings call transcripts for Surrozen, Inc./DE.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more